Literature DB >> 12875991

Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.

Oreste Gallo1, Nicola Schiavone, Laura Papucci, Iacopo Sardi, Lucia Magnelli, Alessandro Franchi, Emanuela Masini, Sergio Capaccioli.   

Abstract

The goal of this study was to analyze the correlation between inducible nitric oxide synthase (iNOS) and COX-2 activities and p53 gene status in head and neck squamous cell carcinomas (HNSCCs) in vivo and in vitro. In a series of 43 HNSCCs we observed an up-regulation of both iNOS and COX-2 pathways in tumor tissues and both activities were correlated each other (rs = 0.612 and P = 0.0002). We also found that p53-mutated HNSCCs (25 cases, 58.1%) showed higher levels of iNOS activity and cGMP in comparison with wild-type p53 tumors (18 cases, 41.9%) (P = 0.0005 and P = 0.01), as well as higher iNOS immunohistochemical expression (P = 0.03). Analogously, higher PgE2 levels were documented in p53-mutated HNSCCs when compared with wild-type p53 tumors (P = 0.015) and COX-2 protein expression was higher in p53-mutated HNSCCs (P = 0.007). A431 cancer cells expressing a p53 temperature-sensitive mutant showed an approximately 1.9- and 2.6-fold decrease in spontaneous NO(2-)/NO(3-) and PgE2 synthesis at permissive temperature, respectively, when compared with the same cells at nonpermissive temperature (P <or= 0.001). Basal levels of iNOS and COX-2 proteins and mRNAs were markedly suppressed by restoration of p53 activity. Our results indicate that p53 gene mutation(s) may be responsible for iNOS and COX-2 up-regulation frequently observed in HNSCCs and suggest that restoration of wild-type p53 expression may interfere with tumor growth by inhibiting iNOS and COX-2 pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875991      PMCID: PMC1868223          DOI: 10.1016/S0002-9440(10)63699-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death.

Authors:  M J Frederick; P R Holton; M Hudson; M Wang; G L Clayman
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice.

Authors:  S Ambs; M O Ogunfusika; W G Merriam; W P Bennett; T R Billiar; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

3.  p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression.

Authors:  Y Sun; Y Sun; L Wenger; J L Rutter; C E Brinckerhoff; H S Cheung
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

4.  Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.

Authors:  A Kropveld; E H Rozemuller; F G Leppers; K C Scheidel; R A de Weger; R Koole; G J Hordijk; P J Slootweg; M G Tilanus
Journal:  Lab Invest       Date:  1999-03       Impact factor: 5.662

5.  Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.

Authors:  M Nishizaki; T Fujiwara; T Tanida; A Hizuta; H Nishimori; T Tokino; Y Nakamura; M Bouvet; J A Roth; N Tanaka
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

6.  Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene?

Authors:  O Gallo; I Sardi; G Pepe; A Franchi; M Attanasio; B Giusti; C Bocciolini; R Abbate
Journal:  Int J Cancer       Date:  1999-07-19       Impact factor: 7.396

7.  Inhibition of cyclooxygenase-2 gene expression by p53.

Authors:  K Subbaramaiah; N Altorki; W J Chung; J R Mestre; A Sampat; A J Dannenberg
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

8.  p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells.

Authors:  S Ambs; W G Merriam; M O Ogunfusika; W P Bennett; N Ishibe; S P Hussain; E E Tzeng; D A Geller; T R Billiar; C C Harris
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

Review 9.  Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review).

Authors:  V Chiarugi; L Magnelli; O Gallo
Journal:  Int J Mol Med       Date:  1998-12       Impact factor: 4.101

Review 10.  The multifaceted roles of nitric oxide in cancer.

Authors:  D A Wink; Y Vodovotz; J Laval; F Laval; M W Dewhirst; J B Mitchell
Journal:  Carcinogenesis       Date:  1998-05       Impact factor: 4.944

View more
  17 in total

1.  Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.

Authors:  Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt; Andrej Cor
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA.

Authors:  Yong-Zhong Wang; You-Qing Cao; Jian-Nong Wu; Miao Chen; Xiao-Ying Cha
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

4.  Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.

Authors:  Dorothea C Torti; Brock C Christensen; Craig A Storm; Joan Fortuny; Ann E Perry; Michael S Zens; Therese Stukel; Steven K Spencer; Heather H Nelson; Margaret R Karagas
Journal:  J Am Acad Dermatol       Date:  2011-05-06       Impact factor: 11.527

5.  Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.

Authors:  Nagehan O Barisik; Suheyla Bozkurt; Mahmut Gumus; Isik Kaygusuz; Nimet Karadayi; Emine Bas; Mahmut Bayik; Tulay Tecimer
Journal:  Diagn Pathol       Date:  2010-03-26       Impact factor: 2.644

6.  Mechanisms of oral carcinogenesis induced by dibenzo[a,l]pyrene: an environmental pollutant and a tobacco smoke constituent.

Authors:  Kun-Ming Chen; Joseph B Guttenplan; Shang-Min Zhang; Cesar Aliaga; Timothy K Cooper; Yuan-Wan Sun; Joseph DelTondo; Wieslawa Kosinska; Arun K Sharma; Kun Jiang; Richard Bruggeman; Kwangmi Ahn; Shantu Amin; Karam El-Bayoumy
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

Review 7.  Cyclooxygenase-2 and its role in colorectal cancer development.

Authors:  Dominique Wendum; Joëlle Masliah; Germain Trugnan; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2004-09-01       Impact factor: 4.064

8.  Correlation between inducible nitric oxide synthase and cyclooxygenase-2 expression in human colorectal adenocarcinoma: a cross-sectional study.

Authors:  Peiman Habibollahi; Mostafa Jamshidiha; Nasser E Daryani; Issa Jahanzad; Mohammad H Ghahremani; Seyed Nasser Ostad
Journal:  Pathol Oncol Res       Date:  2010-01-13       Impact factor: 3.201

9.  Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice.

Authors:  Edoardo Zattra; Christina Coleman; Simin Arad; Elizabeth Helms; Danielle Levine; Evelyn Bord; Alexandra Guillaume; Mohamad El-Hajahmad; Edwin Zwart; Harry van Steeg; Salvador Gonzalez; Raj Kishore; David A Goukassian
Journal:  Am J Pathol       Date:  2009-10-01       Impact factor: 4.307

10.  COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.

Authors:  Reetta Holmila; Diane Cyr; Danièle Luce; Pirjo Heikkilä; Michael Dictor; Torben Steiniche; Tuula Stjernvall; Jette Bornholdt; Håkan Wallin; Henrik Wolff; Kirsti Husgafvel-Pursiainen
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.